Advances in the diagnosis and treatment of MET-variant digestive tract tumors

Figure 3 Mechanisms of MET oncogenic activation. The mechanism of MET carcinogenic activation mainly includes gene mutation, gene amplification and fusion, etc. Through abnormal activation of MET receptor tyrosine kinase, downstream signaling pathways such as RAS/mitogen-activated protein kinase, phosphoinositide 3-kinase/protein kinase B and Janus kinase/signal transducer and activator of transcription are triggered to promote cell proliferation, migration and anti-apoptosis. HGF: Hepatocyte growth factor.